Clinical Trial: A Study of FRaDCs for Ovarian Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Fallopian Tube Carcinosarcoma
Study Type: INTERVENTIONAL
Official Title: FR?DCs Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer
Brief Summary:
The purpose of this study is to determine the response rate to the combination of folate receptor alpha dendritic cells (FRaDCs) plus pembrolizumab in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer.Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.
Read more